title: Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis.
abstract: BACKGROUND
  Artemisinin resistance in Plasmodium falciparum manifests as slow parasite clearance but this measure is also influenced by host immunity, initial parasite biomass and partner drug efficacy. This study collated data from clinical trials of artemisinin derivatives in falciparum malaria with frequent parasite counts to provide reference parasite clearance estimates stratified by location, treatment and time, to examine host factors affecting parasite clearance, and to assess the relationships between parasite clearance and risk of recrudescence during follow-up.
  
  
  METHODS
  Data from 24 studies, conducted from 1996 to 2013, with frequent parasite counts were pooled. Parasite clearance half-life (PC1/2) was estimated using the WWARN Parasite Clearance Estimator. Random effects regression models accounting for study and site heterogeneity were used to explore factors affecting PC1/2 and risk of recrudescence within areas with reported delayed parasite clearance (western Cambodia, western Thailand after 2000, southern Vietnam, southern Myanmar) and in all other areas where parasite populations are artemisinin sensitive.
  
  
  RESULTS
  PC1/2 was estimated in 6975 patients, 3288 of whom also had treatment outcomes evaluate d during 28-63 days follow-up, with 93 (2.8 %) PCR-confirmed recrudescences. In areas with artemisinin-sensitive parasites, the median PC1/2 following three-day artesunate treatment (4 mg/kg/day) ranged from 1.8 to 3.0 h and the proportion of patients with PC1/2 >5 h from 0 to 10 %. Artesunate doses of 4 mg/kg/day decreased PC1/2 by 8.1 % (95 % CI 3.2-12.6) compared to 2 mg/kg/day, except in populations with delayed parasite clearance. PC1/2 was longer in children and in patients with fever or anaemia at enrolment. Long PC1/2 (HR = 2.91, 95 % CI 1.95-4.34 for twofold increase, p < 0.001) and high initial parasitaemia (HR = 2.23, 95 % CI 1.44-3.45 for tenfold increase, p < 0.001) were associated independently with an increased risk of recrudescence. In western Cambodia, the region with the highest prevalence of artemisinin resistance, there was no evidence for increasing PC1/2 since 2007.
  
  
  CONCLUSIONS
  Several factors affect PC1/2. As substantial heterogeneity in parasite clearance exists between locations, early detection of artemisinin resistance requires reference PC1/2 data. Studies with frequent parasite count measurements to characterize PC1/2 should be encouraged. In western Cambodia, where PC1/2 values are longest, there is no evidence for recent emergence of higher levels of artemisinin resistance.
authors.forename: Salim
authors.initials: S
authors.lastname: Abdulla
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Ashley
authors.forename: Quique
authors.initials: Q
authors.lastname: Bassat
authors.forename: Delia
authors.initials: D
authors.lastname: Bethell
authors.forename: Anders
authors.initials: A
authors.lastname: Björkman
authors.forename: Steffen
authors.initials: S
authors.lastname: Borrmann
authors.forename: Umberto
authors.initials: U
authors.lastname: D'Alessandro
authors.forename: Prabin
authors.initials: P
authors.lastname: Dahal
authors.forename: Nicholas P
authors.initials: NP
authors.lastname: Day
authors.forename: Mahamadou
authors.initials: M
authors.lastname: Diakite
authors.forename: Abdoulaye A
authors.initials: AA
authors.lastname: Djimde
authors.forename: Arjen M
authors.initials: AM
authors.lastname: Dondorp
authors.forename: Socheat
authors.initials: S
authors.lastname: Duong
authors.forename: Michael D
authors.initials: MD
authors.lastname: Edstein
authors.forename: Rick M
authors.initials: RM
authors.lastname: Fairhurst
authors.forename: M Abul
authors.initials: MA
authors.lastname: Faiz
authors.forename: Catherine
authors.initials: C
authors.lastname: Falade
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Flegg
authors.forename: Carole
authors.initials: C
authors.lastname: Fogg
authors.forename: Raquel
authors.initials: R
authors.lastname: Gonzalez
authors.forename: Brian
authors.initials: B
authors.lastname: Greenwood
authors.forename: Philippe J
authors.initials: PJ
authors.lastname: Guérin
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Guthmann
authors.forename: Kamal
authors.initials: K
authors.lastname: Hamed
authors.forename: Tran Tinh
authors.initials: TT
authors.lastname: Hien
authors.forename: Ye
authors.initials: Y
authors.lastname: Htut
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Juma
authors.forename: Pharath
authors.initials: P
authors.lastname: Lim
authors.forename: Andreas
authors.initials: A
authors.lastname: Mårtensson
authors.forename: Mayfong
authors.initials: M
authors.lastname: Mayxay
authors.forename: Olugbenga A
authors.initials: OA
authors.lastname: Mokuolu
authors.forename: Clarissa
authors.initials: C
authors.lastname: Moreira
authors.forename: Paul
authors.initials: P
authors.lastname: Newton
authors.forename: Harald
authors.initials: H
authors.lastname: Noedl
authors.forename: Francois
authors.initials: F
authors.lastname: Nosten
authors.forename: Bernhards R
authors.initials: BR
authors.lastname: Ogutu
authors.forename: Marie A
authors.initials: MA
authors.lastname: Onyamboko
authors.forename: Seth
authors.initials: S
authors.lastname: Owusu-Agyei
authors.forename: Aung Pyae
authors.initials: AP
authors.lastname: Phyo
authors.forename: Zul
authors.initials: Z
authors.lastname: Premji
authors.forename: Ric N
authors.initials: RN
authors.lastname: Price
authors.forename: Sasithon
authors.initials: S
authors.lastname: Pukrittayakamee
authors.forename: Michael
authors.initials: M
authors.lastname: Ramharter
authors.forename: Issaka
authors.initials: I
authors.lastname: Sagara
authors.forename: Youry
authors.initials: Y
authors.lastname: Se
authors.forename: Seila
authors.initials: S
authors.lastname: Suon
authors.forename: Kasia
authors.initials: K
authors.lastname: Stepniewska
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Ward
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: White
authors.forename: Peter A
authors.initials: PA
authors.lastname: Winstanley
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage*; D037621:Artemisinins / Q000008:administration & dosage*; D001769:Blood / Q000469:parasitology*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007223:Infant; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D018512:Parasitemia / Q000188:drug therapy*; D010963:Plasmodium falciparum / Q000187:drug effects / Q000302:isolation & purification*; D055815:Young Adult
chemical_list: D000962:Antimalarials; D037621:Artemisinins; C031327:artemisinin